Belgian drugmaker UCB and US biotech Biogen have announced positive top-line results from the Phase III PHOENYCS GO study ...

Research and Manufacturers of America (PhRMA) has taken its legal challenge against the US government’s drug pricing reforms ...

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Otsuka’s Lupkynis (voclosporin) for lupus nephritis ...

Biomedicines (Generate) today announced a multi-target collaboration with Swiss pharm giant Novartis to discover and develop ...

Japanese drugmaker Eisai closed down 2.3% at 5,587 yen today, despite news of regulatory approvals for two of its drugs.

BioAtla has granted Context Therapeutics an exclusive global license for BA3362, a T cell-engaging antibody targeting solid ...

Daiichi Sankyo and AstraZeneca saw a dip in stock prices after announcing that their Phase III TROPION-Breast01 trial for ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

Aptadir Therapeutics, a biotech focused on RNA inhibitor therapies for cancer and genetic conditions, has launched with $1.6 ...

Telix Pharmaceuticals is acquiring US-based RLS Radiopharmacies for $230 million upfront, plus $20 million in performance ...

CSL Vifor today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria ...

Takeda has received Japanese approval for Fruzaqla (fruquintinib) to treat advanced or recurrent colorectal cancer (CRC) that ...